CellCarta

CellCarta operates as a global Contract Research Organization (CRO) laboratory, providing essential biomarker platforms and services to the biopharmaceutical sector. The company is dedicated to addressing intricate scientific testing needs, enabling the advancement of precision medicine through customized biomarker testing solutions. Their expertise encompasses a broad range of analytical capabilities, including mass spectrometry and cytometry, supporting critical research and development phases for therapeutic innovations. CellCarta's commitment lies in unlocking the potential of targeted therapies by delivering high-quality, reliable data for complex biological studies.

With a workforce ranging from 500 to 1,000 employees, CellCarta maintains a significant operational scale, generating $105.8 million in revenue. The company supports its global client base through a network of facilities, facilitating high-throughput sample analysis and complex assay development. This extensive infrastructure and experienced team are pivotal in managing diverse research projects from discovery through clinical development. For detailed information on the personnel behind these scientific endeavors, interested parties can explore Meet CellCarta's team.

Founded in 2002, CellCarta has established a strong presence in the life sciences industry, focusing on areas such as molecular pathology, immune monitoring, and quantitative measurement. The company's strategic offerings are designed to accelerate the development of novel treatments by providing deep biological insights. Competitors in this specialized CRO market include Altasciences and BioPharma Services, highlighting a competitive landscape where CellCarta differentiates itself through its comprehensive biomarker service portfolio and dedication to scientific excellence.